IRC
ALNY icon

Investors Research Corp’s Alnylam Pharmaceuticals ALNY Stock Holding History

Investors Research Corp’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$493 Hold
2
– – ﹤0.01% 740
2026
Q2 		$602 Hold
2
– – ﹤0.01% 755
2026
Q1 		$662 Buy
+2
New +$681 ﹤0.01% 785
2020
Q2 		– Sell
-60
Closed -$7K – 1081
2020
Q1 		$7K Buy
+60
New +$6.93K ﹤0.01% 835

Other funds holding ALNY

MSV
MN Services Vermogensbeheer The Hague, Netherlands $13.4B AUM 37.34% 1-Year Est. Return
LJHT
Laurie J. Hall Trustee $314M AUM 27.43% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.62B AUM 25.73% 1-Year Est. Return
BWMG
Bannerman Wealth Management Group Lewisville, Texas $175M AUM 13.84% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
CPBTD
Central Pacific Bank - Trust Division Honolulu, Hawaii $952M AUM 25.15% 1-Year Est. Return

Investors Research Corp's ALNY Position: Q3 2026 in Review

Investors Research Corp held its Alnylam Pharmaceuticals (ALNY) position steady in Q3 2026 at 2 shares worth $493. The position accounts for ﹤0.01% of the portfolio, ranked #740.

Investors Research Corp first reported a position in ALNY in Q1 2020 and has held it in 4 quarters since. The position peaked at $7K in Q1 2020. 22 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Investors Research Corp held 2 shares of Alnylam Pharmaceuticals worth $493 as of Q3 2026.
  • Investors Research Corp left its Alnylam Pharmaceuticals share count unchanged in Q3 2026.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Investors Research Corp's portfolio in Q3 2026, its #740 holding.
  • Investors Research Corp first reported a position in Alnylam Pharmaceuticals in Q1 2020 and has held it in 4 quarters since.
  • Investors Research Corp's Alnylam Pharmaceuticals position peaked at $7K in Q1 2020.
  • 22 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Investors Research Corp's 13F filing for Q3 2026, filed 7 Oct 2026.